Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Janet Snell-Bergeon to Hypoglycemic Agents

This is a "connection" page, showing publications Janet Snell-Bergeon has written about Hypoglycemic Agents.

 
Connection Strength
  
 
 
4.357
  
  1. Shah VN, Akturk HK, Kruger D, Ahmann A, Bhargava A, Bakoyannis G, Pyle L, Snell-Bergeon JK. Semaglutide in Adults with Type 1 Diabetes and Obesity. NEJM Evid. 2025 Aug; 4(8):EVIDoa2500173.
    View in: PubMed
    Score: 0.496
  2. Garg SK, Kaur G, Renner D, Lanning MS, Mason E, Beatson C, Ciesco K, Snell-Bergeon J. Cardiovascular and Renal Biomarkers in Overweight and Obese Adults with Type 1 Diabetes Treated with Tirzepatide for 21 Months. Diabetes Technol Ther. 2025 Mar; 27(3):152-160.
    View in: PubMed
    Score: 0.485
  3. Snell-Bergeon JK, Kaur G, Renner D, Akturk HK, Beatson C, Garg SK. Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes. Diabetes Technol Ther. 2025 Jan; 27(1):1-9.
    View in: PubMed
    Score: 0.480
  4. Garg SK, Akturk HK, Kaur G, Beatson C, Snell-Bergeon J. Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes. Diabetes Technol Ther. 2024 Jun; 26(6):367-374.
    View in: PubMed
    Score: 0.457
  5. Polsky S, Buschur E, Dungan K, Garcetti R, Nease E, Malecha E, Bartholomew A, Johnson C, Pyle L, Snell-Bergeon J. Randomized Trial of Assisted Hybrid Closed-Loop Therapy Versus Sensor-Augmented Pump Therapy in Pregnancy. Diabetes Technol Ther. 2024 Aug; 26(8):547-555.
    View in: PubMed
    Score: 0.454
  6. Shah VN, Akturk HK, Joseph H, Schneider N, Snell-Bergeon JK. A randomized controlled trial of transition from insulin pump to multiple daily injections using insulin degludec. Diabetes Obes Metab. 2021 08; 23(8):1936-1941.
    View in: PubMed
    Score: 0.376
  7. King J, Buschur E, Garcetti R, Pyle L, Sakamoto C, Snell-Bergeon J, Nease E, Bartholomew A, Dungan K, Polsky S. Changes to insulin pump settings throughout pregnancy for individuals using assisted hybrid closed-loop therapy versus sensor-augmented pump therapy. J Diabetes Complications. 2025 Apr; 39(4):109000.
    View in: PubMed
    Score: 0.122
  8. Brigham TL, Klein MP, Snell-Bergeon JK, Polsky S. Case series of a hybrid closed loop therapy system used in pregnancy. Acta Diabetol. 2025 Sep; 62(9):1439-1449.
    View in: PubMed
    Score: 0.121
  9. Buschur EO, Reedy J, Berget C, Barnard JG, Garcetti R, Nease E, Bartholomew A, Johnson C, Driscoll KA, Dungan KM, Snell-Bergeon JK, Pyle LL, Polsky S. Mixed Methods Randomized Controlled Trial Comparing Quality of Life for Pregnant Women With Type 1 Diabetes Using Hybrid Closed-Loop to Sensor-Augmented Pump Therapy. Endocr Pract. 2025 Apr; 31(4):494-502.
    View in: PubMed
    Score: 0.120
  10. Garg SK, Hirsch IB, Repetto E, Snell-Bergeon J, Ulmer B, Perkins C, Bergenstal RM. Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real-world analysis. Diabetes Obes Metab. 2024 11; 26(11):5202-5210.
    View in: PubMed
    Score: 0.117
  11. King J, Buschur E, Snell-Bergeon J, Pyle L, Dungan K, Garcetti R, Nease E, Bartholomew A, Johnson C, Polsky S. Glycemic Variability in Pregnant Individuals Using Assisted Hybrid Closed-Loop Therapy Versus Sensor-Augmented Pump Therapy. J Diabetes Sci Technol. 2024 Sep; 18(5):1260-1262.
    View in: PubMed
    Score: 0.116
  12. Klein MP, Akturk HK, Snell-Bergeon JK, Shah VN. Reduced Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Therapy in People With Type 1 Diabetes and Genetic Forms of Obesity. J Diabetes Sci Technol. 2025 Mar; 19(2):297-303.
    View in: PubMed
    Score: 0.114
  13. Garg SK, Snell-Bergeon J, Kaur G, Beatson C. Challenges of GLP Analog Use for People with Type 1 Diabetes: Issues with Prior Approvals and Tips for Safer Use. Diabetes Technol Ther. 2024 Jun; 26(6):363-366.
    View in: PubMed
    Score: 0.114
  14. Akturk HK, Dong F, Snell-Bergeon JK, Karakus KE, Shah VN. Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study. J Diabetes Sci Technol. 2025 Mar; 19(2):292-296.
    View in: PubMed
    Score: 0.113
  15. Akturk HK, Giordano D, Champakanath A, Brackett S, Garg S, Snell-Bergeon J. Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes. Diabetes Obes Metab. 2020 04; 22(4):583-589.
    View in: PubMed
    Score: 0.085
  16. Akturk HK, Snell-Bergeon JK, Rewers A, Klaff LJ, Bode BW, Peters AL, Bailey TS, Garg SK. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study. Diabetes Technol Ther. 2018 10; 20(10):639-647.
    View in: PubMed
    Score: 0.078
  17. Snell-Bergeon JK. Diabetes: Cardiovascular benefits of metformin in T1DM. Nat Rev Endocrinol. 2017 10; 13(10):565-566.
    View in: PubMed
    Score: 0.072
  18. Garg SK, Moser EG, Bode BW, Klaff LJ, Hiatt WR, Beatson C, Snell-Bergeon JK. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract. 2013 Jan-Feb; 19(1):19-28.
    View in: PubMed
    Score: 0.052
  19. Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med. 2011 Oct; 28(10):1176-81.
    View in: PubMed
    Score: 0.048
  20. Karakus KE, Snell-Bergeon JK, Akturk HK. Comparison of Computational Statistical Packages for the Analysis of Continuous Glucose Monitoring Data with a Reference Software, "Ambulatory Glucose Profile," in Type 1 Diabetes. Diabetes Technol Ther. 2025 Mar; 27(3):202-208.
    View in: PubMed
    Score: 0.030
  21. Klein MP, Brigham TL, Snell-Bergeon JK, Polsky S. Case Series of Use of an Automated Insulin Delivery System During Hospital Admission for Labor and Delivery. J Diabetes Sci Technol. 2024 Sep; 18(5):1263-1264.
    View in: PubMed
    Score: 0.029
  22. Trojanowski PJ, Pardon A, Reynolds C, O'Donnell HK, Alonso GT, Majidi S, Snell-Bergeon J, Wadwa RP, Driscoll KA. Body mass index moderates the association between diabetes distress and objective self-management behaviours in adolescents with type 1 diabetes and elevated A1Cs. Diabet Med. 2024 Jul; 41(7):e15325.
    View in: PubMed
    Score: 0.028
  23. Gao V, Snell-Bergeon JK, Malecha E, Johnson CA, Polsky S. Clinical Effectiveness of Continuous Glucose Monitoring in Pregnancies Affected by Type 1 Diabetes. Diabetes Technol Ther. 2024 Aug; 26(8):526-535.
    View in: PubMed
    Score: 0.028
  24. Karakus KE, Akturk HK, Alonso GT, Snell-Bergeon JK, Shah VN. Association Between Diabetes Technology Use and Glycemic Outcomes in Adults With Type 1 Diabetes Over a Decade. Diabetes Care. 2023 09 01; 46(9):1646-1651.
    View in: PubMed
    Score: 0.027
  25. Pauley ME, Tommerdahl KL, Snell-Bergeon JK, Forlenza GP. Continuous Glucose Monitor, Insulin Pump, and Automated Insulin Delivery Therapies for Type 1 Diabetes: An Update on Potential for Cardiovascular Benefits. Curr Cardiol Rep. 2022 12; 24(12):2043-2056.
    View in: PubMed
    Score: 0.026
  26. Akturk HK, Snell-Bergeon J, Shah VN. Efficacy and Safety of Tandem Control IQ Without User-Initiated Boluses in Adults with Uncontrolled Type 1 Diabetes. Diabetes Technol Ther. 2022 10; 24(10):779-783.
    View in: PubMed
    Score: 0.025
  27. Champakanath A, Akturk HK, Alonso GT, Snell-Bergeon JK, Shah VN. Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study. Diabetes Care. 2022 03 01; 45(3):750-753.
    View in: PubMed
    Score: 0.025
  28. Sklar J, Pyle L, Snell-Bergeon JK, Garcetti R, Joshee P, Demmitt JK, Polsky S. Glycemic variability and indices of glycemic control among pregnant women with type 1 diabetes (T1D) based on the use of continuous glucose monitoring share technology. J Matern Fetal Neonatal Med. 2022 Dec; 35(25):8968-8974.
    View in: PubMed
    Score: 0.024
  29. Berget C, Akturk HK, Messer LH, Vigers T, Pyle L, Snell-Bergeon J, Driscoll KA, Forlenza GP. Real-world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: Identifying a clinical target for hybrid closed-loop use. Diabetes Obes Metab. 2021 09; 23(9):2048-2057.
    View in: PubMed
    Score: 0.023
  30. Levin P, Hoogwerf BJ, Snell-Bergeon J, Vigers T, Pyle L, Bromberger L. Ultra Rapid-Acting Inhaled Insulin Improves Glucose Control in Patients With Type 2 Diabetes Mellitus. Endocr Pract. 2021 May; 27(5):449-454.
    View in: PubMed
    Score: 0.023
  31. Akturk HK, Snell-Bergeon JK, Shah VN. Continuous Glucose Monitor with Siri Integration Improves Glycemic Control in Legally Blind Patients with Diabetes. Diabetes Technol Ther. 2021 01; 23(1):81-83.
    View in: PubMed
    Score: 0.022
  32. Mulinacci G, Alonso GT, Snell-Bergeon JK, Shah VN. Glycemic Outcomes with Early Initiation of Continuous Glucose Monitoring System in Recently Diagnosed Patients with Type 1 Diabetes. Diabetes Technol Ther. 2019 01; 21(1):6-10.
    View in: PubMed
    Score: 0.020
  33. Maahs DM, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, Hokanson J, Ehrlich J, Garg S, Eckel RH, Rewers MJ. Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population. Diabetes Care. 2005 Feb; 28(2):301-6.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)